Acumen Pharmaceuticals, Inc.

**Signal Note: RA Capital initiates $31.5M position in Acumen (ABOS)** RA Capital's entry into Acumen likely reflects conviction in södintobitus (senoprotein mimetic) for early Alzheimer's disease, where the company is advancing Phase 2b data expected in 2H 2024. The $31.5M stake (~5% of market cap) signals a crossover investor's confidence in a mechanistically differentiated approach targeting soluble tau oligomers, a validated pathology target with less crowded competitive landscape than anti-amyloid monoclonal antibodies.